I. Overall Trend: Triple Leap in Three Years, Strong Rebound After Pandemic

Since statistics began in 2009, the Korean foreign patient market has experienced a complete cycle of "steady growth → pandemic collapse → V-shaped rebound". After plunging to 120,000 in 2020 due to COVID-19, it recovered to 610,000 in 2023, surpassed 1 million to reach 1.17 million in 2024, and doubled again to 2.01 million in 2025 — achieving "doubling growth" for three consecutive years.

Key milestones: Starting from just 60,000 in 2009, cumulative visits surpassed 5 million by 2019; plunged to 120,000 in 2020 due to the pandemic; doubling every year since 2023, with 2.72 million total visits in 2025, and cumulative foreign patients having reached 7.06 million.

II. Country Composition: China Tops the Chart for the First Time; East Asian Trio Dominates

Patients from 201 countries visited Korea, with the top ten source countries/regions (China, Japan, Taiwan (China), USA, Thailand, Singapore, Mongolia, Canada, Vietnam, Indonesia) accounting for nearly 90% of the total. The biggest shift is that China surpassed Japan for the first time, with both China and Taiwan (China) growing over 120%.

Key Observations

Chinese patients surged from about 260,000 to 619,000 (30.8%), a 137.5% increase, surpassing Japan, which had long held the top position. Japan had 600,000 patients (29.8%), just 19,000 fewer than China. Taiwan (China) came in third with 186,000 patients (9.2%), up 122.5%. China and Japan combined account for 60.6% of the total; adding Taiwan (China) brings the East Asian trio to nearly 70%, indicating a highly concentrated structure.

Regional Differentiation

Notably, Russia's department mix has fundamentally shifted: previously dominated by internal medicine and health screening, in 2025 dermatology took the top spot for the first time (5,641 patients). Kazakhstan retains the traditional structure (Internal Medicine 7,741 > Health Screening 5,416 > Dermatology 1,736), with a growth of only 4.9% — the lowest among the top 15 countries.

III. Departments: Dermatology Dominates; Cosmetic Medicine Accounts for 70%

The department mix is extremely skewed — dermatology + plastic surgery account for 74.1% of total visits. Korea's foreign medical label has clearly shifted from "comprehensive medical destination" to "K-Beauty cosmetic medicine hub".

Deeper Implications

Dermatology takes an absolute lead with 1.313 million patients (62.9%), meaning more than 6 out of every 10 foreign patients in Korea come for skin aesthetics. Plastic surgery follows with 233,000 (11.2%); general internal medicine with 192,000 (9.2%).

The growth ranking, however, differs: dentistry emerged as a dark horse with 79.0% growth, with dental clinics (치과의원) growing a staggering 128.9% — signaling that dental medical tourism is becoming a new growth pole, likely tied to high-ticket items like orthodontics and implants serving Chinese and Southeast Asian middle-class consumers.

IV. Medical Institution Mix: Clinic-Dominated; Major Hospitals Bear "Zero Burden"

87.7% of patients are concentrated in primary clinics (의원 level, i.e. clinics) rather than large general hospitals. This directly refutes concerns that foreign patients would crowd out domestic medical resources.

Key fact: Both tertiary and general hospitals' foreign patient bed occupancy is below 1% (0.51% and 0.37% respectively), far below the statutory limits (5% and 8%). Medical tourism in Korea has virtually negligible crowding-out effect on the domestic medical system.

V. Regional Distribution: Seoul Dominates 87.2%; Busan and Jeju Emerge

The geographic distribution is extremely Seoul-centric — 1.76 million patients are concentrated in Seoul, representing 87.2%. This correlates directly with Seoul housing 62.5% of certified foreign patient medical institutions (2,555).

Regional Analysis

Seoul's Gangnam district hosts a vast number of dermatology and plastic surgery clinics. Combined with convenient transit from Incheon Airport to Seoul, and shopping districts like Myeongdong/Gangnam, it forms an integrated "airport — shopping — aesthetic medicine" experience. Busan grew 151.5% and Jeju grew 114.7%, emerging as the two highlights outside the capital region — Busan benefits from short-distance traffic from western Japan (Fukuoka, Osaka), while Jeju leverages its visa-free policy and resort appeal to attract Chinese visitors. Gyeonggi (2.7%) and Incheon (1.3%) have small shares but serve as supporting hubs around the capital region.

VI. Economic Impact: KRW 12.5 Trillion in Medical + Accompanying Spend; KRW 22.8 Trillion in Production Inducement

According to the Korea Institute for Industrial Economics, foreign patients and their companions generated total medical tourism spend of KRW 12.5 trillion (approx. USD 9 billion), of which pure medical spend was KRW 3.3 trillion; this further drove a production-inducement effect of KRW 22.8 trillion (approx. USD 16 billion).

Economic structure: Medical spend is only 26% of total (3.3/12.5), meaning for every dollar foreign patients spend on medical services, they spend three more on shopping, lodging, and food. This "medical + tourism + shopping" composite consumption pattern is the core logic behind Korea's government push for the medical tourism industry.

VII. Growth Drivers Analysis

Jeong Eun-young, Director General of the Industry Policy Bureau at the Korea Ministry of Health and Welfare, attributes the 2025 explosive growth to four key drivers:

First, China's group-traveler visa-free policy. The visa-free policy for Chinese group travelers, implemented from late 2024, directly drove the 137.5% surge in Chinese patients — the single largest variable.

Second, VAT refund policy for cosmetic/plastic surgery. Starting in 2025, foreign patients receiving cosmetic and plastic surgery at designated medical institutions can claim a 10% VAT refund — equivalent to a 10% price cut, highly attractive to price-sensitive Chinese and Southeast Asian customers. In 2024 alone, 1.01 million refunds totaling KRW 95.5 billion were issued.

Third, K-Beauty and Korean Wave content diffusion. Korean cosmetics ranked first for the first time in a 19-country survey on biotech-health industry competitive nations (3rd in 2023); China and Singapore ranked Korean cosmetics #1 in awareness; Taiwan (China) and Thailand ranked #2 — forming a cognitive chain of "recognize K-Beauty → trust Korean dermatology".

Fourth, post-pandemic concentrated release of travel demand. Three years of suppressed medical tourism demand between Korea-Japan and Korea-China erupted in 2024-2025.

VIII. Risks and Concerns

Behind the boom lies structural fragility:

Over-dependence on East Asia as single source: China + Japan + Taiwan (China) account for nearly 70% combined. Any Korea-China political tension or reversal of visa-free policy would immediately impact the overall volume.

Over-concentration in cosmetic medicine: Dermatology + plastic surgery account for 74%, decoupling from the "medical powerhouse" brand image (serious conditions, oncology, cardiovascular, etc.), potentially weakening Korea's international competitiveness in serious medical fields.

Seoul mono-polar structure: 87.2% concentration means regional balance is essentially zero; provincial medical institutions struggle to share in growth.

Russia / Central Asia growth notably slowing: Russia at 21.9% and Kazakhstan at 4.9% are far below average, suggesting traditional serious-medical source markets may be flowing to other destinations (Turkey, India, etc.).

IX. BeautsGO Platform: Transaction Item Rankings

BeautsGO platform's 2025 transactions are concentrated in two main lines: electro-optical category (Ultherapy + Thermage + American Ultherapy) and light medical aesthetics (Skin Booster + Hyaluronic Acid + Gold Microneedling).

Platform Data Observations

Ultherapy leads with 25.1% share, followed by Skin Booster at 20.4%, Hyaluronic Acid 10.0%, Gold Microneedling 8.3%, Botox 5.1%. Electro-optical types combine to 33%, light aesthetics types 38%, with both main lines together accounting for 71% of transactions. This structure aligns with the official "Dermatology 62.9%, Plastic Surgery 11.2%" macro trend — electro-optical anti-aging projects show notable consumption concentration among Chinese medical beauty visitors to Korea.

X. BeautsGO Platform: By Hospital Location in Korea

Based on BeautsGO platform visit trajectories, user access distribution is categorized by hospital location in Korea (precise address classification).

Platform Data Observations

Among hospitals visited by BeautsGO users, Gangnam district takes 47.85% alone, followed by Sinsa (9.93%), Cheongdam (8.91%), Myeongdong (7.27%), Apgujeong (6.03%) — Seoul sub-districts together account for ~90%, highly consistent with the official "Seoul 87.2%". Jeju accounts for 5.21%, significantly higher than the official 2.3%, confirming the "Jeju non-capital rise +114.7%" trend at the industry level. Busan at 1.85% is below the official 3.8% — reflecting that BeautsGO's customer base skews more toward mainland China users, while Busan's main traffic comes from western Japan.

XI. BeautsGO Platform: Visitor Origin Rankings

Based on IP geolocation, Mainland China is the absolute majority of BeautsGO users, internally exhibiting the typical pattern of "first-tier coastal cities lead + central inland follow".

Platform Data Observations

Among BeautsGO users, Mainland China IP accounts for 79.4%, Korea IP 8.4%, with Hong Kong/Macau/Taiwan (China) totaling 6.5%. Within Mainland China, Guangdong (13.9%), Shanghai (12.6%), Beijing (11.1%), Zhejiang (10.1%), and Jiangsu (9.1%) — five provinces totaling 56.8% — reflect the classic "first-tier coastal city lead" pattern.

XII. BeautsGO Platform: Top 10 Transaction Hospitals

BeautsGO platform has high transaction concentration, with the top 10 hospitals contributing nearly half of all transactions.

Platform Data Observations

Top 10 hospitals contribute 45.5% of transactions, with notable head concentration. All 10 hospitals are dermatology clinics / mid-sized plastic surgery clinics, highly consistent with the official "Primary clinics 87.7%" structure — the platform samples reflect the broader trend that Chinese medical beauty customers in Korea concentrate in light aesthetics and mid-sized specialty institutions.

XIII. BeautsGO Platform: Other Key Metrics

The following metrics reflect the entire decision-making behavior of users from "Discovering BeautsGO" to "Transacting in Korea".

Platform Data Observations

BeautsGO users make decisions very prudently — averaging 12 hospitals browsed before deciding, with 38.5% of transacting customers having browsed more than 10 hospitals. The 23-day cycle indicates most users complete the journey from first awareness to final transaction within 3-4 weeks.

Conclusion

From the Korea Ministry of Health and Welfare's official data, the "2.01 million" figure of 2025 marks Korea's official entry into the Asian medical tourism core nation tier. But the deeper truth: this is not a "comprehensive medical victory", but rather an explosion driven by the "K-Beauty + China visa exemption + VAT refund" triple-dividend.

From BeautsGO platform data, Chinese medical beauty customers in Korea exhibit a geographic pattern of "first-tier coastal cities lead, new first-tier mid-tier follow", and an item concentration of "single hit product Ultherapy + light aesthetics combo"; in regional terms, Jeju's penetration significantly exceeds the industry average, confirming the "non-capital rise" trend. User decisions are notably prudent (averaging 12 hospitals browsed, 23-day cycle), with cross-border medical aesthetics' "low repeat purchase + high AOV" features also clearly visible.

Going forward, transitioning from "quantity" to "quality" — maintaining total volume while diversifying source markets, rebalancing departments, and dispersing regions — will be the critical question for whether Korea's medical tourism industry can hold its "Asia #1" position.